TargeGen
A vascular biology-focused biopharmaceutical company, discovers and develops small molecule kinase inhibitors that target.
Employees
Enterprise value
$560m
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
$560m Valuation: $560m | Acquisition | ||
| Total Funding | 000k | ||
Forward Ventures(exited)
Enterprise Partners(exited)
William Blair and Company(exited)
CDIB Capital Group(exited)
CDP Capital Technology Ventures(exited)
BB Biotech Ventures(exited)
VantagePoint Capital Partners(exited)
Pappas Capital(exited)
Chicago Growth Partners(exited)
CTI Life Sciences(exited)
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.